Abstract
Hypertrophic cardiomyopathy (HCM) is an inherited disorder of cardiac sarcomeric proteins characterised by the presence of myocardial hypertrophy in the absence of abnormal loading conditions. Individuals with HCM can remain asymptomatic throughout their lives but many experience chest pain, symptoms of heart failure, syncope and sudden ventricular arrhythmias. Cardiopulmonary exercise testing is an important part of the assessment of patients with HCM who often have reduced peak oxygen consumption and a lower anaerobic threshold compared with healthy age-matched controls. This review will focus on mechanisms of exercise limitation, which are complex and multifactorial, and the options for medical management.
Keywords: Hypertrophic cardiomyopathy, exercise capacity, heart failure, left ventricular tract obstruction, ischaemia, metabolism.
Current Pharmaceutical Design
Title:Mechanisms and Medical Management of Exercise Intolerance in Hypertrophic Cardiomyopathy
Volume: 21 Issue: 4
Author(s): V. Patel, C.H. Critoph and P.M. Elliott
Affiliation:
Keywords: Hypertrophic cardiomyopathy, exercise capacity, heart failure, left ventricular tract obstruction, ischaemia, metabolism.
Abstract: Hypertrophic cardiomyopathy (HCM) is an inherited disorder of cardiac sarcomeric proteins characterised by the presence of myocardial hypertrophy in the absence of abnormal loading conditions. Individuals with HCM can remain asymptomatic throughout their lives but many experience chest pain, symptoms of heart failure, syncope and sudden ventricular arrhythmias. Cardiopulmonary exercise testing is an important part of the assessment of patients with HCM who often have reduced peak oxygen consumption and a lower anaerobic threshold compared with healthy age-matched controls. This review will focus on mechanisms of exercise limitation, which are complex and multifactorial, and the options for medical management.
Export Options
About this article
Cite this article as:
Patel V., Critoph C.H. and Elliott P.M., Mechanisms and Medical Management of Exercise Intolerance in Hypertrophic Cardiomyopathy, Current Pharmaceutical Design 2015; 21 (4) . https://dx.doi.org/10.2174/138161282104141204142436
DOI https://dx.doi.org/10.2174/138161282104141204142436 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiac Metabolism in Diabetes Mellitus
Current Pharmaceutical Design GDF11 Attenuated ANG II-Induced Hypertrophic Cardiomyopathy and Expression of ANP, BNP and Beta-MHC Through Down- Regulating CCL11 in Mice
Current Molecular Medicine Human Embryonic and Induced Pluripotent Stem Cell Based Toxicity Testing Models: Future Applications in New Drug Discovery
Current Medicinal Chemistry The Role of Statins in Preventing the Progression of Congestive Heart Failure in Patients with Metabolic Syndrome
Current Pharmaceutical Design Cardiotonic Steroids in Adaptation to Dietary Salt Intake
Current Clinical Pharmacology Editorial:Circulating Biomarkers in Cardiovascular Diseases – A Field of Theoretical Research or Realistic Clinical Application?
Current Pharmaceutical Biotechnology Subject Index to Volume 2
Current Vascular Pharmacology Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Current Pharmaceutical Design The Clinical Problems of Hypertension Treatment in Hemodialysis Patients
Current Vascular Pharmacology Cardio-Vascular Risks Associated with Clozapine Treatment
Current Psychiatry Reviews Pathogenesis of Age-Related Cataract: A Systematic Review of Proteomic Studies
Current Proteomics Cell Sheet-Based Myocardial Tissue Engineering: New Hope for Damaged Heart Rescue
Current Pharmaceutical Design Clinical and Pharmacological Aspects of Immunoprophylaxis for Respiratory Syncytial Virus Infection in High-Risk Infants
Current Drug Metabolism Circulating Biomarkers for the Diagnosis and Prognosis of Heart Failure
Current Medicinal Chemistry GLP - 1 Analogs: Newer Molecules, Newer Uses
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Atrial Fibrillation: Epidemiology and Peculiarities in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Molecular Basis of Cardioprotection by Erythropoietin
Current Molecular Pharmacology Cardiovascular Surveillance of Duchenne and Becker Muscular Dystrophy and Female Carriers
Current Pediatric Reviews Myocardial Infarction in Systemic Lupus Erythematosus – the Sex-Specific Risk Profile
Current Pharmaceutical Design MicroRNAs and Cardiac Conduction
Current Drug Targets